GRM5 and prostate cancer: Even though all subjects recruited in the current study were diagnosed with non-metastatic prostate cancer before undergoing radiotherapy, it is possible that subtle differences in baseline inflammatory tone, perhaps related to cancer severity, were further exacerbated by mGluR5-related downstream events in response to radiotherapy leading to persistent fatigue 1-year post-radiotherapy.